PMHNP Scope of Practice for General Psychiatry in North Carolina

If you’re a psychiatrist or psychiatric NP wondering whether you can legally prescribe ADHD medications, benzodiazepines, or other controlled substances through telehealth — you’re not alone. The rules have changed more in the past five years than in the previous two decades, and keeping up feels like drinking from a fire hose.

Here’s the straight answer: Yes, psychiatrists can prescribe controlled substances via telehealth in 2026 — but it’s temporary, state-dependent, and about to change again.

The federal government extended COVID-era flexibilities through December 31, 2026, allowing you to prescribe Schedule II-V medications via video consultation without an initial in-person visit. But the DEA is finalizing permanent rules that will reshape how telepsychiatry works, including a new ‘Special Telemedicine Registration’ for prescribers and stricter platform oversight.

And that’s just the federal layer. Each state adds its own requirements — from PDMP checks to NP supervision rules to outright bans on certain prescriptions via telehealth.

This guide breaks down exactly what you need to know to prescribe controlled substances via telehealth legally and confidently in 2026, covering federal DEA rules, state-by-state requirements for California, Texas, Florida, New York, Pennsylvania, and Illinois, and what’s coming next.

What the Current Federal Rules Allow (Through December 2026)

Let’s start with where we are right now.

The DEA’s temporary telehealth flexibilities are extended through the end of 2026. This means you can prescribe Schedule II-V controlled substances to patients via telehealth without requiring an initial in-person examination, as long as you conduct a proper evaluation via real-time audio-video technology and it’s for a legitimate medical purpose.

This applies to:

• Schedule II stimulants (Adderall, Ritalin, Vyvanse for ADHD)
• Schedule III-V medications (buprenorphine, benzodiazepines like Xanax or Klonopin, sleep aids like Ambien)
• New patients you’ve never seen in person
• Established patients (who already have even easier rules — if they’ve ever been seen in person by any provider, there’s no federal restriction on telehealth prescribing)

What You Must Do Under Current Rules

1. Conduct a real-time audio-video evaluation. Phone-only doesn’t cut it for most controlled substances (buprenorphine for opioid use disorder is the exception — audio-only is explicitly allowed for that).

2. Document thoroughly. Your chart should show you did a complete psychiatric evaluation — history, mental status exam, diagnostic reasoning, treatment plan. If the DEA or state board audits you, they need to see this was legitimate clinical care, not a pill mill.

3. Follow standard prescribing protocols. This means checking your state’s PDMP (Prescription Drug Monitoring Program), using e-prescribing where required, and prescribing only within your scope and standard of care.

4. Be licensed in the patient’s state. Telehealth occurs where the patient is located. If your patient is in Florida, you need a Florida medical license (or Florida’s out-of-state telehealth registration). Same goes for your DEA registration — you need one in each state where you’re prescribing controlled substances.

The Reality: This Is Temporary

These flexibilities were supposed to end multiple times already. Each time, the DEA extended them ‘while permanent rules are finalized.’ The current extension runs through December 31, 2026, but the permanent rules are coming — potentially sooner.

Don’t build your entire practice model around rules that might change in six months. Understand what’s likely coming next.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: The DEA’s Proposed Permanent Rules

In January 2025, the DEA announced three proposed rules to replace the temporary flexibilities. If finalized (likely in 2026), here’s what changes:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a new ‘Special Telemedicine Prescriber Registration’ that allows qualified providers to prescribe controlled substances to new patients via telehealth without an in-person exam.

Who qualifies:

• For Schedule III-V medications: any DEA-registered prescriber can apply
• For Schedule II medications: only certain specialists, including board-certified psychiatrists, hospice/palliative care physicians, long-term care facility physicians, and pediatricians (for specific conditions)

What this means for psychiatrists:

If you’re board-certified in psychiatry, you’ll be able to register as a telemedicine prescriber and continue prescribing Adderall, Ritalin, and other Schedule II medications via telehealth to new patients — no in-person visit required. This is huge. It legitimizes what you’re already doing under the temporary rules and makes it permanent.

What this means for PMHNPs:

The proposed rule is less clear for nurse practitioners. If you’re a psychiatric NP, you may qualify for the Schedule III-V registration (which covers many anxiety and sleep medications), but Schedule II prescribing might require working with a supervising psychiatrist who has the special registration — or meeting additional requirements the DEA hasn’t fully detailed yet.

The catch:

You’ll need to apply for this registration (likely an additional fee and paperwork), and there will probably be ongoing compliance requirements like periodic reporting to the DEA or enhanced PDMP checks.

2. Buprenorphine for Opioid Use Disorder: 6-Month Telehealth Window

The DEA is proposing to allow a 6-month supply of buprenorphine via telehealth (including audio-only) before requiring an in-person visit. This is more generous than the current law and reflects how effective telehealth has been for addiction treatment.

If you treat patients with opioid use disorder, this is a win. You can initiate buprenorphine via a phone or video consult and continue for 180 days before scheduling an in-person evaluation.

3. Platform Registration and National PDMP

For the first time, telehealth platforms that facilitate controlled substance prescribing will have to register with the DEA. This is a direct response to cases where companies over-prescribed stimulants with minimal oversight.

The DEA also wants to create a national Prescription Drug Monitoring Program to integrate state PDMP data. This would make it easier to track prescriptions across state lines and identify potential diversion or doctor-shopping.

What this means for you:

If you work with a telehealth platform (like Klarity Health), the platform will handle its own DEA registration and compliance. But expect tighter oversight — both on platforms and on individual prescribers. The days of loosey-goosey telehealth prescribing are over.

State-by-State Breakdown: Where Telehealth Prescribing Gets Complicated

Federal law sets the floor. States can add requirements, but they can’t make things easier than the DEA allows. Here’s what you need to know in six key states:

California: Friendly, But Strict on PDMP

Bottom line: California is one of the best states for telehealth prescribing. No state-specific restrictions on controlled substances via telehealth beyond federal law.

Key requirements:

• CURES PDMP check required before prescribing Schedule II-IV medications for the first time, then every 4 months during ongoing treatment
• 100% e-prescribing mandate for all prescriptions (since January 2022)
• Telehealth can establish a valid patient relationship; no in-person visit required by state law
• Audio-only telehealth is allowed for some services, but for initial controlled substance prescribing, use video to meet the highest standard

NP scope: California is transitioning to full practice authority for experienced PMHNPs. As of 2024-2026, NPs with 3+ years of supervised experience can practice independently in group settings (Category 103) or apply for full independent practice (Category 104). By 2026, many California PMHNPs will be able to prescribe controlled substances without physician oversight.

Licensing: California joined the Interstate Medical Licensure Compact (IMLC) in 2022, making it easier for out-of-state psychiatrists to get licensed. But you still need a California license to treat California patients — the compact just streamlines the process.

Texas: Physician-Only for Schedule II, Strict NP Limits

Bottom line: Texas is restrictive for nurse practitioners but straightforward for psychiatrists.

Key requirements:

• Real-time audio-video required for telehealth prescribing (mental health providers don’t need an in-person presenter)
• Texas PDMP check required before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• No telehealth prescribing of controlled substances for chronic pain management unless the patient has had an in-person visit (doesn’t affect most psychiatric prescribing)

NP scope: This is where Texas gets tough. Psychiatric NPs cannot prescribe Schedule II medications (like Adderall) in outpatient settings. Schedule II authority for NPs is limited to hospital inpatients or hospice patients. For any outpatient telehealth patient in Texas who needs ADHD medication, you need a psychiatrist (MD/DO) to write the prescription.

NPs can prescribe Schedule III-V medications under a physician delegation agreement, but they must always have a supervising physician.

What this means for telehealth platforms: If you’re recruiting Texas providers, you’ll need psychiatrists on staff for any Schedule II prescribing, or pair NPs with supervising physicians who can handle those prescriptions.

Florida: Psychiatric Exception Saves the Day

Bottom line: Florida has strict telehealth controlled substance rules, but psychiatry gets a carve-out.

Key requirements:

• Schedule II controlled substances cannot be prescribed via telehealth — UNLESS it’s for psychiatric treatment, inpatient care, hospice, or nursing home residents
• Schedules III-V can be prescribed via telehealth with no special restrictions
• E-FORCSE PDMP check required before prescribing any controlled substance to patients age 16+
• Out-of-state providers can register as ‘Florida Telehealth Providers’ without getting a full Florida license (but they’re still subject to Florida prescribing rules)

What the psychiatric exception means:

You can prescribe Adderall or other Schedule II stimulants via telehealth in Florida as long as it’s for a psychiatric condition (ADHD qualifies). You cannot prescribe Schedule II opioids for chronic pain via telehealth. Document the psychiatric indication in your chart.

NP scope: Florida does NOT allow independent practice for psychiatric NPs. PMHNPs must have a collaborative agreement with a supervising physician. (Florida created autonomous APRN licenses in 2020, but only for primary care NPs — psychiatry was excluded.)

New York: Progressive and Simple

Bottom line: New York is telehealth-friendly with strong PDMP requirements.

Key requirements:

• I-STOP PDMP check required before prescribing any Schedule II, III, or IV controlled substance (one of the strictest mandates in the country)
• All prescriptions must be e-prescribed (since 2016) — controlled and non-controlled
• Telehealth can establish a patient relationship; no state-mandated in-person visit
• Audio-only telehealth is allowed for some mental health services, but use video for controlled substance prescribing to meet the standard of care

NP scope: New York now allows full practice authority for experienced PMHNPs (those with >3,600 clinical hours). Once you hit that threshold, you can prescribe independently, including controlled substances. New NPs still need a collaborative agreement until they reach the experience requirement.

Licensing: New York is NOT in the IMLC, so out-of-state psychiatrists must go through the full New York licensing process (which can be time-consuming).

Pennsylvania: Standard of Care, No Special Rules

Bottom line: Pennsylvania doesn’t have a comprehensive telehealth law yet, but practice is allowed under general medical regulations.

Key requirements:

• Telehealth encounters must meet the same standard of care as in-person visits
• PA PDMP check required before prescribing opioids or benzodiazepines (and periodically for ongoing treatment)
• E-prescribing required for Schedule II-V controlled substances (since October 2019)

NP scope: Pennsylvania requires PMHNPs to have a collaborative agreement with at least one physician (actually two physicians is the standard for prescriptive authority). NPs can prescribe Schedule II medications for up to 30 days, Schedule III-IV for up to 90 days, with physician oversight.

Licensing: Pennsylvania joined the IMLC in 2021, making it easier for out-of-state psychiatrists to get licensed.

Illinois: Full Practice Available, But with Quirks

Bottom line: Illinois allows full practice authority for experienced NPs but imposes limits on benzodiazepines and Schedule II prescribing.

Key requirements:

• Illinois PDMP check required before prescribing opioids (and recommended for other controlled substances)
• E-prescribing required for all controlled substances (since January 2023)
• Telehealth can establish a patient relationship; no in-person requirement

NP scope: PMHNPs can obtain Full Practice Authority (FPA) after completing 4,000 hours of clinical experience and 250 hours of continuing education. Once you have FPA, you can practice and prescribe independently.

The catch: Even with FPA, Illinois law requires NPs to enter a ‘consultation relationship’ with a physician to prescribe benzodiazepines or Schedule II opioids, and you can only prescribe a 30-day supply at a time. The law’s wording is ambiguous about whether this applies to Schedule II stimulants (like Adderall), but it’s something to be aware of.

What About NP vs. Psychiatrist Scope Nationwide?

The difference between psychiatric NPs and psychiatrists is stark when it comes to prescribing authority:

Psychiatrists (MD/DO):

• Full independent practice authority in all 50 states
• No supervision or collaboration requirements
• Can prescribe all controlled substances Schedule II-V as long as it’s within the standard of care and complies with DEA and state rules

Psychiatric Mental Health Nurse Practitioners (PMHNPs):

• Scope of practice varies wildly by state
• Full practice states (New York, California by 2026, Arizona, Washington, etc.): Can practice and prescribe independently, including controlled substances
• Reduced practice states (Pennsylvania, Ohio, Utah): Require physician collaboration agreements but have significant autonomy once that’s in place
• Restricted practice states (Texas, Florida, South Carolina): Require close physician supervision, often with limits on what they can prescribe (e.g., Texas NPs can’t prescribe Schedule II in outpatient settings)

If you’re a telehealth platform recruiting providers, this matters a lot. A PMHNP who’s fully independent in California can’t practice the same way in Texas without a supervising physician. Plan accordingly.

The Economics: Why Telehealth Prescribing Rules Matter for Your Practice

Let’s talk about the business reality.

Building a psychiatric practice through traditional DIY marketing — SEO, Google Ads, directory listings — is expensive and uncertain. Here’s what providers don’t always see:

Realistic patient acquisition costs through DIY marketing:

• SEO: Takes 6-12 months of consistent investment (often $2,000-5,000/month for content, optimization, and technical work) before generating meaningful patient flow. Most solo providers don’t have the expertise or budget for this.
• Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert. A realistic cost per booked patient is $200-400+ when you factor in wasted ad spend, landing page optimization, and no-show rates from cold leads.
• Directory listings: Psychology Today charges a monthly fee ($29.95+) and you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+) on top of the monthly subscription. Total monthly cost adds up fast.
• All-in DIY marketing: When you factor in agency fees, ad spend, staff time to handle and qualify leads, no-show rates, and months of testing before campaigns work, most providers spend $3,000-5,000+ per month with uncertain ROI.

Why this matters for telehealth prescribing:

If you’re spending thousands per month on marketing with no guarantees, you’re also dealing with the complexity of multi-state licensing, state-specific prescribing rules, PDMP registrations, DEA registrations in each state, malpractice coverage, and compliance overhead.

The alternative: Platforms like Klarity Health use a pay-per-appointment model. You pay a standard listing fee per qualified patient lead who books with you. No upfront marketing spend. No monthly subscriptions. No wasted clicks. Just patients who are already matched to your specialty and availability.

Compare the economics:

• DIY route: $3,000-5,000/month in marketing → uncertain patient volume → you handle all compliance, scheduling, billing, and platform tech
• Platform route: $0 upfront → pay only when a qualified patient books → pre-built telehealth infrastructure, insurance credentialing handled, multi-state compliance support

For most psychiatrists and PMHNPs — especially those starting out or scaling quickly — eliminating the marketing risk entirely is the smarter economic choice. You control your schedule, see the patients you want, and only pay when you’re actually generating revenue.

And with controlled substance prescribing rules in flux, working with a platform that stays on top of compliance (like ensuring proper DEA registrations, PDMP integrations, and state-specific workflows) removes a massive headache.

Compliance Checklist: What You Must Do to Prescribe Controlled Substances via Telehealth Safely

Here’s your practical compliance checklist for 2026:

Before You See Your First Telehealth Patient

• [ ] Get licensed in every state where your patients are located. Check if the state is in the IMLC (for MDs) or has out-of-state telehealth registration options (like Florida).
• [ ] Obtain DEA registrations in each state where you’ll prescribe controlled substances. Your DEA number must be tied to the state where the patient receives the prescription.
• [ ] Register with each state’s PDMP. Many states require registration before you can query the database.
• [ ] Set up EPCS (Electronic Prescribing of Controlled Substances). Most states mandate e-prescribing for controlled substances. Your system needs two-factor authentication and must comply with DEA requirements.
• [ ] Verify your malpractice insurance covers telehealth in all states where you practice.
• [ ] If you’re a PMHNP, confirm your scope of practice in each state. Do you need a collaborative agreement? Are there limits on Schedule II prescribing?

Before You Prescribe a Controlled Substance

• [ ] Conduct a thorough evaluation via real-time audio-video. Document history, mental status exam, diagnosis, and treatment rationale.
• [ ] Check the state PDMP for the patient’s controlled substance history. (Required in most states before prescribing Schedule II-IV medications.)
• [ ] Obtain informed consent for telehealth. Document that the patient understands they’re receiving care via telemedicine and agrees to it.
• [ ] Verify the patient’s location. Confirm they’re physically located in a state where you’re licensed.
• [ ] Document the medical necessity. Especially for Schedule II prescriptions in states like Florida, make it clear the medication is for a psychiatric condition.

Ongoing Compliance

• [ ] Check the PDMP periodically. California requires it every 4 months during ongoing controlled substance treatment. Other states have similar requirements.
• [ ] Keep up with state-specific rules. Subscribe to your state medical board’s updates. Telehealth laws are changing fast.
• [ ] Complete required training. The federal MATE Act (2023) requires all DEA registrants to complete 8 hours of training on substance use disorder and pain management. If you’re renewing your DEA registration, you’ll need to attest to this.
• [ ] Watch for the DEA’s final rules. When the permanent telemedicine rules are published (likely 2026), you may need to apply for a Special Telemedicine Registration or adjust your practice model.

FAQ: Telehealth Controlled Substance Prescribing

Q: Can I prescribe Adderall to a new patient via telehealth in 2026?

A: Yes, under current federal rules (extended through December 31, 2026), you can prescribe Schedule II stimulants like Adderall to a new patient via telehealth after conducting a proper evaluation via audio-video consultation. You must be licensed in the patient’s state, check the state PDMP, and follow all state-specific requirements.

State exceptions: In Texas, only physicians (not NPs) can prescribe Schedule II in outpatient settings. In Florida, you can prescribe Schedule II via telehealth only for psychiatric treatment (which ADHD qualifies as).

Q: What happens when the DEA’s temporary rules expire?

A: The temporary rules currently run through December 31, 2026. The DEA is expected to finalize permanent rules before then. The proposed permanent rules include a Special Telemedicine Registration that would allow board-certified psychiatrists to continue prescribing Schedule II medications via telehealth. Stay tuned for updates — this is the most important regulatory change coming in 2026.

Q: Can psychiatric NPs prescribe controlled substances via telehealth independently?

A: It depends on the state. In full practice states like New York (for experienced NPs with >3,600 hours) and California (transitioning to full practice by 2026), yes. In restricted states like Texas and Florida, no — NPs need physician supervision and may face limits on Schedule II prescribing.

Q: Do I need an in-person visit before prescribing benzodiazepines via telehealth?

A: Not under current federal rules (through 2026). You can prescribe benzodiazepines (Schedule IV) via telehealth after an appropriate evaluation via audio-video. However, always check your state’s requirements — some states may have additional rules about high-risk medications.

Q: What’s the difference between the Ryan Haight Act and current DEA rules?

A: The Ryan Haight Act (2008) generally requires at least one in-person medical evaluation before prescribing controlled substances via the internet. However, this requirement has been suspended since March 2020 under federal public health emergency exceptions, which have been extended multiple times. The current extension runs through December 31, 2026. Once the DEA finalizes permanent rules, some form of in-person visit or special telemedicine registration will likely be required — but psychiatrists will have pathways to continue telehealth prescribing.

Q: Can I do phone-only visits for controlled substance prescribing?

A: Generally, no. The DEA’s guidance requires real-time audio-video (two-way interactive communication) for telehealth prescribing of most controlled substances. The exception is buprenorphine for opioid use disorder, which can be prescribed after an audio-only (telephone) consultation under current rules and the proposed permanent rule.

Q: Do I need separate DEA registrations for each state where I practice telehealth?

A: Yes. If you’re prescribing controlled substances to patients in multiple states, you need a DEA registration in each state (tied to an address in that state, even if it’s just a registered agent address). This is true even for telehealth-only practice.

Q: What happens if I prescribe a controlled substance to a patient in a state where I’m not licensed?

A: You’re practicing medicine illegally in that state and could face disciplinary action from that state’s medical board, DEA sanctions, and potential criminal charges. Don’t do it. Always verify the patient’s location and ensure you’re licensed there before prescribing.

The Bottom Line: Prescribe with Confidence, But Stay Alert

Here’s what you need to remember:

Yes, you can prescribe controlled substances via telehealth in 2026 — but the rules are temporary, state-dependent, and about to change. The DEA is finalizing permanent rules that will likely require special telemedicine registrations and impose tighter oversight on platforms.

For psychiatrists: You’re in a good position. Board-certified psychiatrists will likely qualify for Schedule II telemedicine prescribing under the proposed rules. Just stay compliant with state PDMP checks, e-prescribing mandates, and licensing requirements.

For psychiatric NPs: Your scope varies wildly by state. In full practice states, you’re golden. In restricted states like Texas and Florida, you’ll need physician collaboration and may face limits on Schedule II prescribing.

For everyone: The economics of building a telehealth practice through DIY marketing are brutal. Spending $3,000-5,000/month on ads and SEO with uncertain results isn’t sustainable for most providers. Platforms that handle patient acquisition, compliance, and infrastructure — and charge only when patients book — offer a far better ROI.

As regulations tighten, the providers who succeed in telepsychiatry will be those who combine clinical excellence with smart business choices. That means staying on top of compliance, working with platforms that handle the regulatory complexity, and focusing your time on patient care instead of marketing and administrative overhead.

Join Klarity Health’s Provider Network

Klarity Health takes the guesswork out of telehealth compliance and patient acquisition. Our platform handles:

✅ Pre-qualified patients matched to your specialty and availability
✅ Multi-state licensing and DEA compliance support
✅ Integrated PDMP checks and e-prescribing
✅ HIPAA-compliant telehealth infrastructure
✅ Insurance and cash-pay patient flow
✅ Pay-per-appointment model — no upfront costs or monthly fees

You control your schedule. We handle the rest.

Ready to grow your practice without the marketing risk? Learn more about joining Klarity Health’s provider network →

Citations

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Care for Patients While Ensuring Patient Safety.’ Press Release, January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Substance Abuse and Mental Health Services Administration (SAMHSA). ‘Elimination of the DATA Waiver (X-Waiver) Requirement.’ Updated 2023. https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

4. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ Healthcare Industry Analysis, March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board. ‘Prescriptive Authority and Physician Supervision FAQs.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices